We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Automated, Motorized Endoscopic Ultrasound Biopsy Device Advances Precision Medicine

By MedImaging International staff writers
Posted on 04 May 2022
Image: Precision-GI Endoscopic Biopsy Device (Photo courtesy of Limaca Medical)
Image: Precision-GI Endoscopic Biopsy Device (Photo courtesy of Limaca Medical)

Endoscopic biopsy is performed by a gastroenterologist who accesses the targeted gastrointestinal (GI) tumor utilizing an ultrasound visualization endoscope. Suspect GI tumor locations include submucosal lesions, mediastinal masses, lymph nodes, intraperitoneal masses, and within GI related organs such as the pancreas and liver. Today's endoscopic biopsy devices have limitations in consistently obtaining quality tissue with sufficient quantity, which can result in sample tissue fragmentation, inadequate tissue amount, and blood contamination. Now, a new endoscopic ultrasound biopsy device featuring a unique motorized, automated rotational cutting needle is designed to obtain biopsies for definitive diagnosis of pancreatic cancer and other life-threatening GI cancers more quickly and less traumatically than current products.

Limaca Medical’s (Yokneam, Israel) Precision-GI device is designed to obtain tumor tissue within or adjacent to the GI tract. It is deployed and operated through an instrument channel in the endoscope to biopsy the tumor. While all existing endoscopic ultrasound fine needle biopsy (EUS-FNB) devices require manual hand operation, Precision GI features a unique motorized, automated rotational cutting needle for successful tissue acquisition. The automated design provides for more efficient and effective diagnosis of GI cancers since it is designed to yield significantly superior quality and quantity of diagnostically relevant biopsy tissue.

Initial cases from Limaca's comparative feasibility clinical study, which is ongoing, demonstrates that Precision GI obtained contiguous intact core tissue samples fully adequate for definitive diagnosis of pancreatic lesions. The clean, non-contaminated tissue samples provided a high percentage of tumor content, with less blood and extraneous fluids. Limaca’s Precision-GI endoscopic ultrasound biopsy product has received a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Under the program, the FDA will provide Limaca with the opportunity to provide its feedback during the pre-market phase and prioritized review of the device submission.

"We are pleased with the FDA's decision to grant the Breakthrough Device Designation to Precision-GI," said Carl Rickenbaugh, Limaca's CEO. "At Limaca, our vision is to ensure that endoscopic biopsies always achieve a definitive diagnosis to enable optimal and timely GI-cancer treatment. We are dedicated to the mission to provide a far better endoscopic biopsy experience for the endoscopist and patient, with the goal to achieve a faster, more efficient biopsy yield with highly consistent results. With the Breakthrough Device Designation, we look forward to accelerating our progress toward our goal of obtaining the FDA's 510(k) clearance to bring Precision-GI to patients in the US in the near future."

"Precision-GI is an automated, motorized endoscopic biopsy product that has the potential to improve our biopsy results for the evaluation of gastrointestinal malignancies. Endoscopic biopsy is a highly specialized, high skill procedure. We welcome the innovation of Precision-GI which can provide automation and standardization of outcomes with less variation from operator to operator," said Seth A. Gross, MD, Clinical Chief, Division of Gastroenterology and Hepatology, NYU Langone Health. "Our field is driving toward patient centric individualized cancer therapy, known as Precision Medicine, which requires consistently high quality and quantity of endoscopic biopsy tissue, enabling optimal matching of the tumor's genetic profile to personalize a patient's treatment plan."

Related Links:
Limaca Medical

Ultrasound Imaging System
P12 Elite
X-ray Diagnostic System
FDX Visionary-A
Digital X-Ray Detector Panel
Acuity G4
New
Diagnostic Ultrasound System
DC-80A

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Nuclear Medicine

view channel
Image: The diagnostic tool could improve diagnosis and treatment decisions for patients with chronic lung infections (Photo courtesy of SNMMI)

Novel Bacteria-Specific PET Imaging Approach Detects Hard-To-Diagnose Lung Infections

Mycobacteroides abscessus is a rapidly growing mycobacteria that primarily affects immunocompromised patients and those with underlying lung diseases, such as cystic fibrosis or chronic obstructive pulmonary... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.